IDYA: ideayabio.com Net earnings per share for the last 12 months

Symbol and logo of brand IDEAYA Biosciences, Inc. (IDYA)

The financial stability of IDEAYA Biosciences (IDYA) is constrained by a lack of recurring revenue and a dependence on external capital. The trailing 12-month EPS, with a metric value of -4.45, illustrates this volatility. These risks are mitigated by a staff of leading scientists with high option-based incentives and strategic alliances with pharma behemoths, which provide the company with the resources necessary to develop targeted therapy.

IDYA (IDEAYA Biosciences) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/13/2026

Analytical breakdowns for IDEAYA Biosciences

- share price and expert price forecast:
Stock Quotes IDEAYA Biosciences|IDYA - Fair Value Consensus
- market capitalization information:
Market Valuation IDEAYA Biosciences, Inc.|IDYA - Aggregate Business Value
- balance sheet net asset value indicators:
Book Value per Share IDEAYA Biosciences|IDYA - Book Capitalization|Market Value to Book Value Ratio ideayabio.com|IDYA - Aggregate Asset Value
- business debt structure and liquidity details:
Total Debt to Capital IDEAYA Biosciences|IDYA - Long-Term Indebtedness to Equity|Short-Term Debt to Capital IDEAYA Bio|IDYA - Company Cumulative Debt|Debt to Book Value IDEAYA Biosciences, Inc.|IDYA - Amount of Long-Term Liabilities|Company Short-Term Debts IDEAYA Biosciences|Quick Ratio ideayabio.com
- net income and valuation multiples indicators:
IDYA - Company Profit|Future Profit IDEAYA Biosciences|IDYA - Company Value to Net Income|Projected Price to Earnings IDEAYA Biosciences, Inc.|IDYA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple IDEAYA Biosciences, Inc.|IDYA - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) IDEAYA Biosciences|IDYA - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months ideayabio.com|IDYA - Earnings per share increase in current year|Earnings growth forecast for next year IDEAYA Biosciences
- sales and revenue data:
IDYA - Revenue and Sales Volume|Company Projected Revenue IDEAYA Biosciences|IDYA - Price-to-Sales Ratio|Forward Price-to-Revenue Multiple IDEAYA Biosciences, Inc.
Basic company analysis:IDEAYA Biosciences - IDYA
Manufactured products of IDEAYA Biosciences Inc

Analyzing the net income per share over the last 12 months allows for an assessment of the efficiency of IDEAYA Biosciences (IDYA) in developing targeted oncology drugs, accounting for diversification through partnerships. This indicator captures the rolling total of profit while excluding the impact of share volume, enabling the identification of historical extremes and neutralizing temporary distortions from one-off transactions to evaluate capital stability.

Who IDEAYA Biosciences competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (exelixis.com)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|ELVN (Enliven Pharma) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) ORIC Corp|Earnings per share for the last twelve months Relay Therapeutics (RLAY)|NRIX (nurixtx.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) TYRA (Tyra Biosciences)|Net earnings per share for the trailing year Verastem Oncology|Monte Rosa Tx - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Cullinan Corp|IMRX (Immuneering Corporation) - Net earnings per share for the last 12 months|CCCC: Earnings per share for the last four quarters|BDTX (Black Diamond Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Repare Therapeutics, Inc. RPTX|Net earnings per share (EPS TTM) PMVP|karyopharm.com - Earnings per share for the last 12 months|Propanc Biopharma - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|Aileron Therapeutics - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics) - Net earnings per share (EPS TTM)